A phase II trial of copper gluconate/disulfiram (CX-02) in patients with metastatic breast cancer
Phase of Trial: Phase II
Latest Information Update: 01 May 2017
Price : $35 *
At a glance
- Drugs Copper-gluconate/disulfiram (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 May 2017 According to a Cantex Pharmaceuticals media release, this trial is expected to begin in 2018.
- 11 Apr 2017 New trial record
- 04 Apr 2017 This trial is expected to begin in the second half of 2017, according to a Cantex Pharmaceuticals media release.